A Stable Prostacyclin Analogue Reduces High Serum TNF-α Levels in Diabetic Patients
| Autor: | Kentaro Fujiwara, Nobuki Hayakawa, Atsushi Suzuki, Keiko Yamamoto, Y Sawai, Naohisa Oda, Mutsuko Nagata, Akio Nagasaka, Shigeo Imamura, Mitsuyasu Itoh |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Diabetic neuropathy medicine.drug_class Endocrinology Diabetes and Metabolism medicine.medical_treatment Prostaglandin Prostacyclin Monoclonal antibody Body Mass Index chemistry.chemical_compound Endocrinology Diabetic Neuropathies Oral administration Internal medicine Diabetes mellitus Internal Medicine medicine Humans Aged Glycated Hemoglobin Tumor Necrosis Factor-alpha business.industry General Medicine Middle Aged medicine.disease Epoprostenol Beraprost Cytokine Diabetes Mellitus Type 2 chemistry Female business medicine.drug |
| Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 112:390-394 |
| ISSN: | 1439-3646 0947-7349 |
| DOI: | 10.1055/s-2004-821024 |
| Popis: | AIMS To confirm whether a prostacyclin (prostaglandin I (2)) affects the increased TNF-alpha concentration in sera of diabetic patients, we measured serum TNF-alpha concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Twelve of 20 type II diabetic patients were investigated for follow up-study and 6 of those patients were for therapy with Beraprost for diabetic neuropathy. SUBJECTS AND METHODS Serum TNF-alpha concentration was quantified by EASIA using monoclonal antibodies directed against distinct epitopes of TNF-alpha. RESULTS In diabetic patients, serum TNF-alpha concentration was significantly increased compared with that of healthy subjects. The augmented TNF-alpha concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin I (2)) analogue for 5 weeks without any changes of blood glucose levels. CONCLUSIONS Stable prostacyclin analogue administration for a short term period reduced increased TNF-alpha levels in diabetic patients, not through the improved hyperglycemic condition but another pathway, probably a cAMP system. These results imply that treatment with the prostacyclin analogue may contribute to the prevention of progression in diabetic complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|